Form D · Other Technology
54Gene, Inc.
Washington, DC · CIK 0001809111
Offering snapshot reported Sep 24, 2021 · SEC filing
- Reported sold
- $25.1M Offering amount: $37.5M
- Investors reported
- 27 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 8, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 24, 2021 | Initial | $25,119,754 | No comparison | 27 | SEC filing |
| Apr 14, 2020 | Initial | $18,651,384 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-414541
Source: Form D, filed Sep 24, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Delali Attipoe | Director, Executive |
| Abasi Ene Obong | Director, Executive, Promoter |
| Patrice Milos | Director |
| Olufunmilayo Falusi Olopade | Director |
| Yassine Oussaifi | Director |
| Jenny Yip | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
1100 15 Th Street, Nw
Washington, DC, 20005
Washington, DC, 20005